Professor Jin Li & Professor Joon Oh Park: Carrying the Torch Forward with Unity and Collaboration — FACO as a Platform for Advancing Comprehensive Academic Cooperation and the Joint Progress of Asian Clinical Oncology
Editor’s Note: The 13th Federation of Asian Clinical Oncology (FACO) Annual Meeting was grandly held in Shanghai on October 24–25, 2025. As a collaborative organization jointly initiated by the…
ISEH 2025 | Harvesting the Fruits of Collaboration: China–Japan Symposium on Stem Cells and Cell Therapy Opens a New Chapter
Editor’s Note: As autumn scents the air with osmanthus blossoms, leading scientists gathered in Kumamoto for an intellectual feast. The 54th Annual Scientific Meeting of the International Society for Experimental…
ESMO Global Insight | Professor Andrea Necchi: Disitamab Vedotin Plus Immunotherapy Nearly Doubles Overall Survival in Advanced HER2-Expressing Urothelial Carcinoma
The combination of antibody–drug conjugates (ADCs) with immunotherapy has delivered major breakthroughs across several tumor types, including urothelial carcinoma. At the 2025 European Society for Medical Oncology (ESMO) Congress, results from a pivotal Phase III trial (LBA7) were presented showing that the HER2-targeted ADC disitamab vedotin, combined with the PD-1 inhibitor toripalimab, nearly doubled overall survival compared with chemotherapy as first-line treatment for patients with HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC). This novel regimen, centered on an innovative ADC, may redefine first-line therapy—though several key questions remain.
Highlights from the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025)
At the recent FACO 2025 Conference held in Shanghai, Dr. Joon Oh Park, President of KSMO and President-elect of FACO, shared his perspectives on the evolving landscape of cancer treatment…
13th FACO Annual Academic Conference Grandly Held in Shanghai! Leading Experts from China, Japan, and South Korea Gather to Foster Clinical Oncology
Editor’s Note: Promoting collaboration through exchange, and seeking mutual success through cooperation — on October 24, 2025, the 13th Federation of Asian Clinical Oncology (FACO) Annual Conference was grandly held…
ESMO Interview | Dr. Bryan Li: From Bladder Removal to Bladder Preservation, Perioperative Immunotherapy Reshapes MIBC Treatment
Editor's Note: Immunotherapy has rapidly developed in recent years, achieving remarkable clinical results in the treatment of advanced bladder cancer. With the continued advancement of clinical research, the application of…
Oriental Insight | Professors Xiaoyun Mao and Wen Xu’s Team Publishes a Comprehensive Review on Engineered Upconversion Nanoparticles for Precision Theranostics in Breast Cancer
Breast cancer remains the most common malignancy among women, with persistently high incidence and mortality rates. Its heterogeneity, drug resistance, and the toxicity associated with conventional therapies continue to challenge clinical management.In recent years, rare-earth-doped upconversion nanoparticles (UCNPs) have attracted growing attention in breast cancer research owing to their unique optical properties, tunable synthesis, and flexible functionalization strategies.Recently, the research teams led by Professor Xiaoyun Mao from the First Affiliated Hospital of China Medical University and Professor Wen Xu from the School of Physics and Materials Engineering, Dalian Minzu University, published a cover review in Theranostics titled 'Engineered Upconversion Nanoparticles for Breast Cancer Theranostics.'This review systematically summarizes the progress of UCNP-based strategies in breast cancer diagnosis and therapy, while also discussing challenges in clinical translation and future development directions.
The 11th Qingdao Breast Disease Conference | Professor Xin Wang: Opportunities and Challenges in Omitting Local Therapy After Neoadjuvant Treatment
Editor’s Note: With the expanding role of neoadjuvant therapy in breast cancer, pathologic complete response (pCR) has become an important indicator for evaluating treatment efficacy. Whether patients who achieve pCR…